2022
Characteristics and treatment of hospitalized pregnant women with COVID-19
Sekkarie A, Woodruff R, Whitaker M, Kramer M, Zapata L, Ellington S, Meaney-Delman D, Pham H, Patel K, Taylor C, Chai S, Kawasaki B, Meek J, Openo K, Weigel A, Leegwater L, Como-Sabetti K, Ropp S, Muse A, Bennett N, Billing L, Sutton M, Talbot H, Hill M, Havers F, Team C. Characteristics and treatment of hospitalized pregnant women with COVID-19. American Journal Of Obstetrics & Gynecology MFM 2022, 4: 100715. PMID: 35970493, PMCID: PMC9371979, DOI: 10.1016/j.ajogmf.2022.100715.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCOVID-19COVID-19 VaccinesFemaleHumansInfant, NewbornPregnancyPregnant WomenSARS-CoV-2SteroidsConceptsSymptomatic COVID-19Pregnant womenSystemic steroidsCOVID-19 vaccinationVaccination statusPregnant patientsNonpregnant womenCOVID-19Laboratory-confirmed SARS-CoV-2 infectionPregnancy statusPropensity score-matched cohortCOVID-19-Associated Hospitalization Surveillance NetworkSARS-CoV-2 infectionMedical chart abstractionTreatment-eligible patientsAdverse pregnancy outcomesSymptomatic pregnant womenCOVID-19 vaccination statusHospitalized pregnant womenNon-Hispanic blacksImplementation of treatmentHospitalized womenChart abstractionClinical characteristicsPregnancy outcomes
2021
Risk Factors for Severe COVID-19 in Children
Woodruff R, Campbell A, Taylor C, Chai S, Kawasaki B, Meek J, Anderson E, Weigel A, Monroe M, Reeg L, Bye E, Sosin D, Muse A, Bennett N, Billing L, Sutton M, Talbot H, McCaffrey K, Pham H, Patel K, Whitaker M, McMorrow M, Havers F. Risk Factors for Severe COVID-19 in Children. Pediatrics 2021, 149: e2021053418. PMID: 34935038, PMCID: PMC9213563, DOI: 10.1542/peds.2021-053418.Peer-Reviewed Original ResearchConceptsSevere COVID-19Adjusted risk ratioPopulation-based ratesHospitalized childrenRisk factorsCOVID-19Laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infectionAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSevere coronavirus disease 2019COVID-19-Associated Hospitalization Surveillance NetworkNon-Hispanic black childrenCoronavirus 2 infectionChronic lung diseaseConfidence intervalsCoronavirus disease 2019COVID-19 vaccineTube dependenceAirway abnormalitiesDiabetes mellitusIllness severityLung diseaseRisk ratioMedical recordsEvaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States
Hook SA, Hansen AP, Niesobecki SA, Meek JI, Bjork JKH, Kough EM, Peterson MS, Schiffman EK, Rutz HJ, Rowe AJ, White JL, Peel JL, Biggerstaff BJ, Hinckley AF. Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States. Vaccine 2021, 40: 298-305. PMID: 34895785, DOI: 10.1016/j.vaccine.2021.11.065.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineSurvey-weighted descriptive statisticsMultivariable multinomial logistic regression modelsCross-sectional studyLyme disease incidenceHigh incidence areaCross-sectional surveyLogistic regression modelsSafety concernsMultinomial logistic regression modelsVaccine uptakeAdults 45Vaccine parametersVaccine candidatesVaccine attitudesPrevention optionsHealthcare providersWeb-based surveyVaccineSociodemographic characteristicsIncidence areaLyme diseaseDisease incidenceIncidence